How iX Biopharma turned conviction into opportunity
After losing a key licensing partner, the Singapore pharmaceutical company continued advancing its lead drug programme. That persistence opened new pathways to commercialisation – and unlocked value beyond the laboratory.
In a story of perseverance and adaptation, Singapore's iX Biopharma turned a setback into a significant opportunity. The company's lead drug programme, centred around its proprietary drug-delivery platform WaferiX, faced an unexpected roadblock when its licensing partner for Wafermine walked away in late 2023. However, this setback did not deter the team at iX Biopharma.
Instead, they remained steadfast in their belief in the potential of Wafermine and quickly shifted gears to reassess their commercial strategy. Chairman and CEO Eddy Lee encouraged the team to keep an open mind, with Chief Commercial Officer Eva Tan recalling his memorable request: "He asked to add a new slide to the deck: a picture of a magician pulling a rabbit out of a hat.
And his message to the board was: 'How do you know we won't pull a rabbit out of the hat?'" Following these discussions, the United States Department of Defense (DoD) saw the potential of Wafermine for battlefield pain management and awarded iX Biopharma a $41 million (S$53 million) contract to complete the programme's development.
This funding paved the way for early deployment of the drug through an emergency use authorisation (EUA). For iX Biopharma, the contract was more than just financial support; it reinforced their confidence in Wafermine's potential and the drug delivery technology behind it. The company's success story is not confined to Wafermine alone. iX Biopharma also boasts a diverse portfolio of consumer health formulations, ranging from hormone therapies and peptides to longevity products.
Unlike Wafermine, these formulations can already reach patients through licensed US compounding pharmacies and the company's WaferiX telehealth platform. Recognizing this, the company has decided to expand its US presence, establishing a manufacturing joint venture and relocating wafer production to the US. This expansion, coupled with the creation of Ligo Pharma, a standalone consumer health business, allows iX Biopharma to develop its two complementary growth engines—Pharmaceutical and Consumer Health—on different timelines, each with its own strategic focus, capital structure, and growth pathway.
Written by urgent.news from Channel News Asia's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
